356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 356-OR
Author(s):  
JONATHAN E. SHAW ◽  
FADY T. BOTROS ◽  
RALEIGH MALIK ◽  
CHARLES ATISSO ◽  
HELEN M. COLHOUN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Function ◽  
Post Hoc Analysis ◽  
Post Hoc

Abstract #295 GLP-1 Receptor Agonists and Death From Any Cause in Elderly Patients with Type 2 Diabetes Mellitus: A Post-Hoc Analysis

2018 ◽  
Vol 24 ◽  
pp. 80-81
Author(s):  
Konstantinos Toulis ◽  
Krishna Gokhale ◽  
G. Neil Thomas ◽  
Wasim Hanif ◽  
Krishnarajah Nirantharakumar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly Patients ◽  
Post Hoc Analysis ◽  
Receptor Agonists ◽  
Post Hoc

Abstract #245 Efficacy and Safety of Semaglutide in Elderly Subjects with Type 2 Diabetes: A Post Hoc Analysis of the Sustain 7 Trial

2018 ◽  
Vol 24 ◽  
pp. 51-52
Author(s):  
Vanita Aroda ◽  
Danny Sugimoto ◽  
David Trachtenbarg ◽  
Mark Warren ◽  
Gurudutt Nayak ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Subjects ◽  
Efficacy And Safety ◽  
Post Hoc Analysis ◽  
Post Hoc

Efficacy and safety of semaglutide in elderly subjects with type 2 diabetes: a post hoc analysis of the SUSTAIN 7 trial

2019 ◽  
Author(s):  
W Schmidt ◽  
V Aroda ◽  
D Sugimoto ◽  
D Trachtenbarg ◽  
M Warren ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Subjects ◽  
Efficacy And Safety ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Suvanjaa Sivalingam ◽  
Emil List Larsen ◽  
Daniel H. van Raalte ◽  
Marcel H. A. Muskiet ◽  
Mark M. Smits ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Type 2 Diabetes ◽  
Nucleic Acid ◽  
Urinary Excretion ◽  
Post Hoc Analysis ◽  
Significant Difference ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Post Hoc

AbstractGlucagon-like peptide 1 receptor agonists have shown cardioprotective effects which have been suggested to be mediated through inhibition of oxidative stress. We investigated the effect of treatment with a glucagon-like peptide 1 receptor agonist (liraglutide) on oxidative stress measured as urinary nucleic acid oxidation in persons with type 2 diabetes. Post-hoc analysis of two independent, randomised, placebo-controlled and double-blinded clinical trials. In a cross-over study where persons with type 2 diabetes and microalbuminuria (LIRALBU, n = 32) received liraglutide (1.8 mg/day) or placebo for 12 weeks in random order, separated by 4 weeks of wash-out. In a parallel-grouped study where obese persons with type 2 diabetes (SAFEGUARD, n = 56) received liraglutide (1.8 mg/day), sitagliptin (100 mg/day) or placebo for 12 weeks. Endpoints were changes in the urinary markers of DNA oxidation (8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG)) and RNA oxidation [8-oxo-7,8-dihydroguanosine (8-oxoGuo)]. In LIRALBU, we observed no significant differences between treatment periods in urinary excretion of 8-oxodG [0.028 (standard error (SE): 0.17] nmol/mmol creatinine, p = 0.87) or of 8-oxoGuo [0.12 (0.12) nmol/mmol creatinine, p = 0.31]. In SAFEGUARD, excretion of 8-oxodG was not changed in the liraglutide group [2.8 (− 8.51; 15.49) %, p = 0.62] but a significant decline was demonstrated in the placebo group [12.6 (− 21.3; 3.1) %, p = 0.02], resulting in a relative increase in the liraglutide group compared to placebo (0.16 nmol/mmol creatinine, SE 0.07, p = 0.02). Treatment with sitagliptin compared to placebo demonstrated no significant difference (0.07 (0.07) nmol/mmol creatinine, p = 0.34). Nor were any significant differences for urinary excretion of 8-oxoGuo liraglutide vs placebo [0.09 (SE: 0.07) nmol/mmol creatinine, p = 0.19] or sitagliptin vs placebo [0.07 (SE: 0.07) nmol/mmol creatinine, p = 0.35] observed. This post-hoc analysis could not demonstrate a beneficial effect of 12 weeks of treatment with liraglutide or sitagliptin on oxidatively generated modifications of nucleic acid in persons with type 2 diabetes.

651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 651-P
Author(s):  
ENZO BONORA ◽  
JUAN P. FRIAS ◽  
RALEIGH MALIK ◽  
ANITA KWAN ◽  
SOHINI RAHA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Post Hoc Analysis ◽  
Induce Weight Loss ◽  
Post Hoc ◽  
Baseline Bmi ◽  
Higher Doses

80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 80-OR
Author(s):  
ROBERT F. KUSHNER ◽  
MELANIE J. DAVIES ◽  
JOHN DEANFIELD ◽  
W. TIMOTHY GARVEY ◽  
OLE JEPPESEN ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Cardiometabolic Risk ◽  
Cardiometabolic Risk Factors ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document